Epidermal growth factor as a biologic switch in hair growth cycle [PDF]
, 2002 The hair growth cycle consists of three stages known as the anagen (growing), catagen (involution), and telogen (resting) phases. This cyclical growth of hair is regulated by a diversity of growth factors.
Chan, SY, Mak, KKL
core +1 more source
Effects of EGFR Expression on Anti-tumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts [PDF]
, 2010 Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).
Dicker, A. P. +3 more
core +2 more sources
Technology in Cancer Research & Treatment, 2020 Background: To investigate the mechanism of microRNA9 in inhibiting proliferation and migration of lung squamous cell carcinoma cells via neuron-restricted silencing factor/epidermal growth factor receptor.
Kangning Wang MD +4 more
doaj +1 more source
The epidermal growth factor receptor conundrum [PDF]
Cancer, 2010 Soluble epidermal growth factor receptor (sEGFR), a cell surface and serum protein derived from an alternately spliced human EGFR transcript, is recognized by 2 therapeutic antibodies approved by the US Food and Drug Administration: cetuximab and panitumumab.
Jason A, Wilken +2 more
openaire +2 more sources
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [PDF]
, 2013 Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy.
Cooper, Chris +7 more
core +2 more sources
Tumor Biology, 2017 The mutations of epidermal growth factor receptor are detected in gastric cancer, indicating its suitability as a target for receptor tyrosine kinase inhibitors, as well as a marker for clinical outcome of chemotherapeutic treatments. However, extraction
Xiu-Qin Shi +4 more
doaj +1 more source
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [PDF]
, 2017 Introduction: Clinical guidelines have recommended a 1-year trastuzumab regimen as standard care for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however ...
Ansaripour, A. (Amir) +2 more
core +4 more sources
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
Clinics, 2012 OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Carlos E. Bacchi +5 more
doaj +1 more source
SAGE Open Medical Case Reports, 2023 A 71-year-old non-smoker woman was admitted to our hospital because of left front chest pain. A computed tomography scan showed a large mass of >7.0 cm in the lower left part of the lung and multiple organ metastases in the liver, brain, bone, and left ...
Sosuke Matsumura +7 more
doaj +1 more source
Rapamycin induces transactivation of the EGFR and increases cell survival. [PDF]
, 2009 The mammalian target of rapamycin (mTOR) signaling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular ...
Chaturvedi, D +4 more
core +2 more sources